Larson Financial Group LLC Makes New $130,000 Investment in STAAR Surgical (NASDAQ:STAA)

Larson Financial Group LLC purchased a new stake in STAAR Surgical (NASDAQ:STAA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,728 shares of the medical instruments supplier’s stock, valued at approximately $130,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of STAAR Surgical by 313.9% in the first quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 992 shares in the last quarter. Cape Investment Advisory Inc. acquired a new stake in shares of STAAR Surgical in the fourth quarter valued at approximately $42,000. Covestor Ltd boosted its stake in shares of STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock valued at $103,000 after buying an additional 754 shares during the period. Quest Partners LLC acquired a new stake in STAAR Surgical during the fourth quarter worth approximately $146,000. Finally, Virtu Financial LLC bought a new position in STAAR Surgical during the 1st quarter worth $289,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on STAA. BTIG Research raised their price objective on STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Morgan Stanley lowered shares of STAAR Surgical from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $50.00 to $37.00 in a research report on Monday, July 15th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, August 8th. Canaccord Genuity Group lowered their price objective on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating on the stock in a research note on Thursday, August 8th. Finally, Stifel Nicolaus reduced their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, August 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $45.57.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock opened at $31.12 on Friday. STAAR Surgical has a 52-week low of $26.66 and a 52-week high of $52.68. The company has a fifty day moving average of $39.03 and a 200-day moving average of $40.50. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 100.39 and a beta of 0.58.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $0.15 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.09). The company had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $95.22 million. STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 EPS. On average, equities research analysts forecast that STAAR Surgical will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling at STAAR Surgical

In other news, Director Arthur C. Butcher bought 1,315 shares of STAAR Surgical stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $37.99 per share, for a total transaction of $49,956.85. Following the acquisition, the director now owns 4,208 shares of the company’s stock, valued at $159,861.92. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.